Daily Sepsis Research Analysis
Mechanistic and translational advances in sepsis research today include identification of plasma polymeric Ig receptor (pIgR) as a prognostic biomarker and driver of lung injury, a randomized trial suggesting intravenous omega-3 fatty acids reduce sepsis-associated delirium and ICU resource use, and a pragmatic adaptive trial design to optimize post-discharge remote monitoring after sepsis. Together these works span pathophysiology, adjunctive therapy, and health services innovation.
Summary
Mechanistic and translational advances in sepsis research today include identification of plasma polymeric Ig receptor (pIgR) as a prognostic biomarker and driver of lung injury, a randomized trial suggesting intravenous omega-3 fatty acids reduce sepsis-associated delirium and ICU resource use, and a pragmatic adaptive trial design to optimize post-discharge remote monitoring after sepsis. Together these works span pathophysiology, adjunctive therapy, and health services innovation.
Research Themes
- Immunopathology and prognostic biomarkers in sepsis
- Adjunctive therapies for sepsis-associated complications
- Post-discharge remote monitoring and adaptive trial methods
Selected Articles
1. Plasma polymeric immunoglobulin receptor exacerbates lung injury in
Human proteomics and ELISA linked elevated plasma pIgR to worse prognosis in pneumonia-induced sepsis. In mice, intravenous recombinant pIgR increased mortality, and mechanistic experiments indicate that pIgR interacts with IgM to drive alveolar type 2 epithelial pyroptosis, worsening lung injury.
Impact: This study uncovers a novel pro-pathogenic role for circulating pIgR in sepsis and positions it as a prognostic biomarker and potential therapeutic target.
Clinical Implications: Plasma pIgR could support risk stratification in pneumonia-induced sepsis and motivates testing strategies that block the pIgR–IgM axis to mitigate alveolar epithelial pyroptosis and lung injury.
Key Findings
- Quantitative proteomics and ELISA associated higher plasma pIgR with worse prognosis in pneumonia-induced sepsis.
- Intravenous recombinant pIgR increased mortality in murine sepsis models.
- Mechanistically, plasma pIgR likely interacts with IgM to induce AT2 epithelial pyroptosis, exacerbating lung injury.
- Plasma pIgR emerges as both a prognostic biomarker and a pro-pathogenic factor in infectious diseases.
Methodological Strengths
- Integrated human clinical proteomics/ELISA with in vivo murine sepsis models and primary AT2 cell studies
- Consistent mechanistic narrative linking biomarker signal to epithelial pyroptosis
Limitations
- Human data are associative and do not establish causality
- Translational generalizability from mouse models to human sepsis requires confirmation; sample size details are not reported
Future Directions: Validate pIgR prognostic value in multicenter cohorts, quantify effect sizes, and develop/assess inhibitors or neutralizing strategies targeting the pIgR–IgM pathway.
BACKGROUND: Polymeric immunoglobulin receptors (pIgR) may enhance mucosal immunity or worsen an infection through transcytosis of polymeric immunoglobulins or infectious pathogens. The function of plasma pIgR in infections remains unknown. METHODS: The association of plasma pIgR with the occurrence and prognosis of sepsis was investigated using human plasma. The role and underlying mechanisms of plasma pIgR were investigated in mouse models of sepsis and primary alveolar type 2 epithelial cells (AT2). RESULTS: Quantitative proteomic and ELISA analysis revealed a significant association between plasma pIgR and the prognosis of patients of pneumonia-induced sepsis. Intravenous administrations of recombinant pIgR (r_pIgR) increased the mortality in mouse models of CONCLUSIONS: This study demonstrates that plasma pIgR is a potential prognostic marker for sepsis, and likely contributes to AT2 pyroptosis and sepsis lethality through interaction with IgM, indicating a broad pro-pathogenic role of plasma pIgR in infectious diseases.
2. Treatment of delirium in intensive care patients with sepsis using daily intravenous infusions with omega-3 fatty acids.
In a randomized, placebo-controlled single-center trial (n=220), daily IV omega-3 fatty acids reduced delirium days over the first 10 days, ICU length of stay, and ventilation days in sepsis patients, without affecting mortality. Twice-daily standardized assessments strengthened outcome measurement.
Impact: Provides randomized clinical evidence for an adjunctive, immunomodulatory therapy to reduce sepsis-associated delirium and resource utilization.
Clinical Implications: Consider IV omega-3 as an adjunct in sepsis patients at high risk for delirium, while awaiting multicenter confirmation and safety profiling; protocols should include standardized delirium monitoring.
Key Findings
- Randomized trial (n=220) showed significantly fewer delirium days with IV omega-3 versus placebo (p=0.010).
- ICU length of stay and mechanical ventilation days were reduced in the omega-3 group (p=0.008 and p=0.001, respectively).
- No significant mortality difference between groups.
- Delirium was assessed twice daily using RASS and CAM, enhancing measurement rigor.
Methodological Strengths
- Randomized, placebo-controlled design with standardized delirium assessments (RASS, CAM)
- Clinically meaningful secondary endpoints (ICU LOS, ventilation days)
Limitations
- Single-center study; generalizability requires multicenter replication
- Blinding and allocation concealment procedures are not fully described; no mortality benefit detected
Future Directions: Conduct multicenter, adequately powered RCTs to confirm effects on delirium and evaluate impacts on long-term cognition, mortality, and safety; explore dosing and timing optimization.
BACKGROUND: The development of delirium is closely linked to inflammatory processes. Omega-3 fatty acids can modulate the immune response and may contribute to reducing the incidence of sepsis-associated delirium (SAD). AIMS: To investigate the effects of omega-3 fatty acids on delirium in patients with sepsis. MATERIALS AND METHODS: In a single-center clinical trial, 220 intensive care patients diagnosed with sepsis were randomly assigned to receive daily intravenous infusions of either an omega-3 fish oil emulsion or a placebo. Delirium was assessed twice daily using the Richmond Agitation-Sedation Scale (RASS) and the Confusion Assessment Method (CAM). The primary outcome was the duration of delirium during the first 10 days of admission. Secondary outcomes included the duration of mechanical ventilation, length of intensive care unit (ICU) stay, and mortality. RESULTS: Compared to the control group, the omega-3 group exhibited significantly fewer days with delirium episodes (p = 0.010), shorter ICU stays (p = 0.008), and fewer mechanical ventilation days (p = 0.001). However, there was no statistically significant difference in mortality between the two groups. CONCLUSION: Omega-3 fatty acids may effectively reduce the risk of delirium in sepsis patients, highlighting their potential as a therapeutic intervention in this population.
3. Design and methods of an adaptive trial to test comparative effectiveness of readmission reduction approaches following infection and sepsis hospitalizations (ACCOMPLISH).
ACCOMPLISH is a pragmatic adaptive RCT comparing four remote patient monitoring strategies versus usual care after sepsis/LRTI hospitalization, with the primary endpoint of 90-day home days. Adaptive randomization will favor better-performing arms over time, and outcomes include readmissions, function, and quality of life.
Impact: Introduces a pragmatic, adaptive framework to optimize transitional care after sepsis using RPM, with patient-centered endpoints and scalable implementation relevance.
Clinical Implications: If effective, RPM strategies could reduce readmissions and increase days at home post-sepsis, informing policy and care pathways; the design supports learning healthcare systems.
Key Findings
- Pragmatic adaptive RCT testing four post-discharge RPM strategies versus structured telephonic support after sepsis/LRTI.
- Primary endpoint is 90-day home days, integrating mortality and time at home; readmissions captured via claims.
- Quarterly adaptive randomization increases allocation to better-performing arms over time.
- Registered trial (NCT04829188) with secondary outcomes including function and health-related quality of life.
Methodological Strengths
- Pragmatic adaptive design with patient-centered composite endpoint (home days)
- Use of claims data for robust readmission capture and incorporation of functional/QoL measures
Limitations
- Methods paper without results; effectiveness and implementation feasibility remain to be demonstrated
- Potential variability in RPM adherence and care team response across sites may affect generalizability
Future Directions: Complete trial execution, report effectiveness and cost-effectiveness, and perform subgroup analyses (e.g., sepsis phenotypes) to personalize post-discharge monitoring.
BACKGROUND: The months following hospitalization for sepsis and lower respiratory tract infection can often be very difficult for patients. Many will have subsequent clinical deterioration, which for some requires hospital readmission while, for others, transition to hospice care may be more appropriate. Unfortunately, there is a lack of high-quality evidence regarding how best to support patients in this period. Remote patient monitoring (RPM) technology can allow patients to remain at home yet be monitored for early signs of clinical deterioration. However, what should be monitored, and how any response should be coordinated, is unclear. We designed a pragmatic adaptive randomized clinical trial to determine the effect of four post-discharge RPM strategies comprising low vs. high intensity monitoring and standard versus enhanced care team response on 90-day hospital readmission rates. METHODS: Adults admitted to the hospital with sepsis or lower respiratory tract infection (index admission) are recruited and randomized to usual care (structured telephonic support [STS]) or one of four post-discharge RPM care models in addition to STS. The primary outcome is home days, a composite endpoint of 90-day mortality and the number of days a patient spends at home within 90 days after discharge to home from the index admission. Hospital readmissions will be measured primarily by health insurance claims data. Secondary endpoints, such as functional status and health-related quality of life, will be measured at baseline and 90 days. An adaptive randomization process is run quarterly, improving patients' chances to be randomized to the highest-performing intervention arms. DISCUSSION: The study evaluates different post-discharge monitoring and workforce strategies to increase home days. With a large, representative sample and pragmatic adaptive study design, this research aims to deliver key insights into effective remote discharge monitoring technology and workforce deployment, benefiting patients, providers, and payers. TRIAL REGISTRATION: This trial is registered at clinicaltrials.gov (NCT04829188). https://clinicaltrials.gov/study/NCT04829188. Date of registration: January 4, 2021.